Octinoxate

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Octinoxate
Accession Number
DB09496
Type
Small Molecule
Groups
Approved, Investigational
Description

Octinoxate is a cinnamate ester and common ingredient in sunscreen and other skin care products to minimize DNA photodamage. It was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. It is often combined with nanoparticles or other water-resistant liposomes in formulations to increase the localization at the epidermis and decrease the risk of percutaneous absorption. Its use in pharmaceutical and cosmetic formulations is approved by FDA.

Structure
Thumb
Synonyms
  • ethylhexyl methoxycinnamate
  • ethylhexyl p-methoxycinnamate
  • Octinoxate
  • octyl methoxycinnamate
  • parsol
External IDs
Eusolex 2292 / Uvinul MC80
Active Moieties
NameKindUNIICASInChI Key
2-Ethylhexyl 4-phenylbenzophenone-2'-carboxylateunknown93NOD9WBCS75005-95-7TWAOKHHZKFMFMD-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
No7 Protect and Perfect Foundation Sunscreen Broad Spectrum SPF 15 CalicoEmulsion1.5 g/30gTopicalBoots Retail Usa Inc2012-10-26Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
125 Fl Moisture Whip Lipstick-stk Top 50mg/gStickTopicalMaybelline Canada1996-12-311998-07-11Canada
2-Power Fabric SPF 25Cream67 mg/1mLTopicalLaboratoires Biocosm Sarl2017-12-25Not applicableUs
25 Creme 410CreamTopicalMultaler & Cie2004-06-012008-03-28Canada
275lw Long Wearing Lipstick 50mg/gStickTopicalMaybelline Canada1996-12-311998-07-11Canada
4-IN-1 Liquid 14-hour Wear Foundation SPF 15EmulsionTopicalPUR MINERALS2013-02-202017-03-28Canada
6 Creme 410CreamTopicalMultaler & Cie2004-12-012008-06-25Canada
6 Creme 410 TeinteeCream5 g/100gTopicalMULTALER & CIE S.A.S2011-02-152017-05-11Us
6 Creme 410 TeinteeCream5 %TopicalMultaler & Cie2004-12-032013-07-31Canada
6 Lait SolaireLotionTopicalMultaler & Cie2004-12-012013-07-31Canada
675rl Revitalizing Lip Indulgence - Stk 7.5%StickTopicalMaybelline Canada1996-12-311999-07-30Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
01 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
01 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
02 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
02 Cushion Spf45 SunscreenOctinoxate (5 g/100mL) + Octisalate (5 g/100mL) + Octocrylene (2.5 g/100mL) + Titanium dioxide (13.5 g/100mL) + Zinc oxide (8 g/100mL)LiquidTopicalCOIZ CO LTD2019-06-30Not applicableUs
02 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
03 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
03 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
04 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
04 Moisture Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Zinc oxide (3.9 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-06Not applicableUs
05 Balancing Foundation SPF 15Octinoxate (3.75 mg/0.5mL) + Octisalate (2.5 mg/0.5mL) + Titanium dioxide (1.45 mg/0.5mL)EmulsionTopicalThe Body Shop, Wake Forest2009-09-062017-10-05Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
4362 First Aid KitOctinoxate (7.5 g/100mL) + Ammonia (0.045 g/0.3mL) + Avobenzone (1 g/100mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Homosalate (5 g/100mL) + Hydrocortisone acetate (1 g/100g) + Isopropyl alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Neomycin sulfate (3.5 mg/1g) + Octisalate (5 g/100mL) + Oxybenzone (6 g/100mL) + Polymyxin B sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL) + Water (98.6 mL/100mL)TopicalHoneywell Safety Products USA, Inc.2018-09-13Not applicableUs
Abalone Crystaldouble EX BbOctinoxate (2 g/100mL) + Adenosine (0.04 g/100mL) + Nicotinamide (2 g/100mL) + Octocrylene (3 g/100mL) + Titanium dioxide (9.9 g/100mL)CreamTopicalC&bcosmetic Co.,ltd.2017-03-10Not applicableUs
Abalone Crystaldouble EX CcOctinoxate (7 g/100mL) + Adenosine (0.04 g/100mL) + Nicotinamide (2 g/100mL) + Titanium dioxide (4.694 g/100mL)CreamTopicalC&bcosmetic Co.,ltd.2017-03-10Not applicableUs
AHC Premium Intense Contour BalmOctinoxate (1.5 g/50mL) + Adenosine (0.02 g/50mL) + Aluminium tristearate (0.04 g/50mL) + Aluminum hydroxide (0.45 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 CST) (1.3 g/50mL) + Talc (2.05 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (0.96 g/50mL)CreamTopicalCarver Korea Co.,Ltd.2014-01-152017-11-22Us
Alphaquin HPOctinoxate (75 mg/1g) + Hydroquinone (40 mg/1g) + Oxybenzone (50 mg/1g)CreamTopicalStratus Pharmaceuticals1993-01-012017-02-01Us
Condition and Enhance System Full-size Non-surgicalOctinoxate (75 mg/1mL) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Zinc oxide (90 mg/1mL)KitTopicalOMP, INC.2007-08-20Not applicableUs
Condition and Enhance System Travel-size Non-surgicalOctinoxate (75 mg/1mL) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Zinc oxide (90 mg/1mL)KitTopicalOMP, INC.2007-08-20Not applicableUs
Condition and Enhance System Travel-size SurgicalOctinoxate (75 mg/1mL) + Hydroquinone (40 mg/1g) + Hydroquinone (40 mg/1g) + Zinc oxide (90 mg/1mL) + Zinc oxide (185 mg/1g)KitTopicalOMP, INC.2007-08-20Not applicableUs
Conju Princess UV Sun BlockOctinoxate (0.075 mL/1mL) + Avobenzone (0.03 mL/1mL) + Enzacamene (0.05 mL/1mL) + Titanium dioxide (0.0249 mL/1mL) + Zinc oxide (0.01 mL/1mL)CreamTopicalConju Inc2010-12-18Not applicableUs
Conju Princess UV Sun BlockOctinoxate (0.075 mL/1mL) + Avobenzone (0.03 mL/1mL) + Enzacamene (0.05 mL/1mL) + Titanium dioxide (0.0249 mL/1mL) + Zinc oxide (0.01 mL/1mL)CreamTopicalConju Inc2010-12-18Not applicableUs
Categories
UNII
4Y5P7MUD51
CAS number
5466-77-3
Weight
Average: 290.3972
Monoisotopic: 290.188194698
Chemical Formula
C18H26O3
InChI Key
YBGZDTIWKVFICR-JLHYYAGUSA-N
InChI
InChI=1S/C18H26O3/c1-4-6-7-15(5-2)14-21-18(19)13-10-16-8-11-17(20-3)12-9-16/h8-13,15H,4-7,14H2,1-3H3/b13-10+
IUPAC Name
2-ethylhexyl (2E)-3-(4-methoxyphenyl)prop-2-enoate
SMILES
[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC

Pharmacology

Indication

As an active ingredient in sunscreens and lip balms. Used for protection against damaging effects of sun rays.

Associated Conditions
Pharmacodynamics

Acts as a photoprotective agent that protects the skin by preventing and minimizing the damaging effects of ultraviolet (UV) rays of natural light. The cellular effects of UV irradiation include DNA damage, cell cycle arrest, immunological depression, apoptosis, and transcriptional changes 7.

Mechanism of action

Absorbs UV-B (predominantly) and UV-A rays while accumulating in the outermost layer of the epidermis. Like any other photoprotective agents, octinoxate prevents the damage to cells and deoxyribonucleic acid (DNA) by reducing the p53 protein expression following UV exposure 7 and also increases the skin's tolerability to UV rays 6.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Can be systemically absorbed after skin application, being found in the deeper layers of the stratum corneum as well as urine, plasma, and breast milk 2. The mean maximum plasma concentration detected after application of 2mg/cm2 sunscreen was 7ng/mL in women and 16ng/mL in men 6.

Volume of distribution
Not Available
Protein binding

None

Metabolism

Can undergo hepatic metabolism when systematically absorbed. Can be enzymatically degraded by lipases in the stratum corneum where esters undergo hydrolysis 2. Degrade into photoproducts when exposed to sunlight, which leads to a decrease in UV absorption efficiency 6.

Route of elimination

Can be detected in urine in unchanged form 4.

Half life
Not Available
Clearance
Not Available
Toxicity

Slightly hazardous in case of skin contact, eye contact, ingestion and inhalation. Octinoxate may form reactive singlet oxygen species and induce anti-estrogenic effects 8. UV-induced molecular breakdown of octinoxate may interfere with cellular processes or induce oxidative damage in human skin 6. The NOAEL (no observed adverse effect level) is 450 mg/kg bw/day for fertility and reproductive performance, for systemic parental and developmental toxicity in Wistar rats 3.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Octinoxate which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Monteiro MS, Ozzetti RA, Vergnanini AL, de Brito-Gitirana L, Volpato NM, de Freitas ZM, Ricci-Junior E, dos Santos EP: Evaluation of octyl p-methoxycinnamate included in liposomes and cyclodextrins in anti-solar preparations: preparations, characterizations and in vitro penetration studies. Int J Nanomedicine. 2012;7:3045-58. doi: 10.2147/IJN.S28550. Epub 2012 Jun 20. [PubMed:22787399]
  2. Mota Ade C, de Freitas ZM, Ricci Junior E, Dellamora-Ortiz GM, Santos-Oliveira R, Ozzetti RA, Vergnanini AL, Ribeiro VL, Silva RS, dos Santos EP: In vivo and in vitro evaluation of octyl methoxycinnamate liposomes. Int J Nanomedicine. 2013;8:4689-701. doi: 10.2147/IJN.S51383. Epub 2013 Dec 10. [PubMed:24376350]
  3. Schneider S, Deckardt K, Hellwig J, Kuttler K, Mellert W, Schulte S, van Ravenzwaay B: Octyl methoxycinnamate: two generation reproduction toxicity in Wistar rats by dietary administration. Food Chem Toxicol. 2005 Jul;43(7):1083-92. [PubMed:15833384]
  4. Janjua NR, Mogensen B, Andersson AM, Petersen JH, Henriksen M, Skakkebaek NE, Wulf HC: Systemic absorption of the sunscreens benzophenone-3, octyl-methoxycinnamate, and 3-(4-methyl-benzylidene) camphor after whole-body topical application and reproductive hormone levels in humans. J Invest Dermatol. 2004 Jul;123(1):57-61. [PubMed:15191542]
  5. Hayden CG, Cross SE, Anderson C, Saunders NA, Roberts MS: Sunscreen penetration of human skin and related keratinocyte toxicity after topical application. Skin Pharmacol Physiol. 2005 Jul-Aug;18(4):170-4. Epub 2005 May 20. [PubMed:15908756]
  6. Latha MS, Martis J, Shobha V, Sham Shinde R, Bangera S, Krishnankutty B, Bellary S, Varughese S, Rao P, Naveen Kumar BR: Sunscreening agents: a review. J Clin Aesthet Dermatol. 2013 Jan;6(1):16-26. [PubMed:23320122]
  7. Duale N, Olsen AK, Christensen T, Butt ST, Brunborg G: Octyl methoxycinnamate modulates gene expression and prevents cyclobutane pyrimidine dimer formation but not oxidative DNA damage in UV-exposed human cell lines. Toxicol Sci. 2010 Apr;114(2):272-84. doi: 10.1093/toxsci/kfq005. Epub 2010 Jan 13. [PubMed:20071424]
  8. Maipas S, Nicolopoulou-Stamati P: Sun lotion chemicals as endocrine disruptors. Hormones (Athens). 2015 Jan-Mar;14(1):32-46. [PubMed:25885102]
  9. The Dermatology Review: Octinoxate [Link]
External Links
Human Metabolome Database
HMDB0061861
KEGG Drug
D05225
PubChem Compound
5355130
PubChem Substance
347827864
ChemSpider
4511170
ChEBI
88667
ChEMBL
CHEMBL1200608
Wikipedia
Octyl_methoxycinnamate
ATC Codes
D02BA02 — Octinoxate
AHFS Codes
  • 84:80.00 — Sunscreen Agents
MSDS
Download (61 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherSystemic Exposure to Sunscreen Ingredients1
2CompletedSupportive CareAdvanced Malignant Neoplasm / Dermatologic Complication / Dermatologic Complications / Neoplasms, Malignant1
2RecruitingTreatmentAcute Promyelocytic Leukemia With PML-RARA / Leukemias1
3Active Not RecruitingTreatmentAcute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
4CompletedTreatmentMelasma1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus1
Not AvailableCompletedDiagnosticDermatitis, Photocontact1
Not AvailableCompletedTreatmentFoot Dryness in Patients With NIDDM / Foot Transepidermal Water Loss in Patients in NIDDM1
Not AvailableTerminatedTreatmentDiaper Rash1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical67 mg/1mL
CreamTopical5 g/100g
CreamTopical5 %
CreamTopical0.9 g/30mL
GelCutaneous
CreamTopical65 mg/1mL
SprayCutaneous
LotionTopical0.975 g/15g
SalveTopical
GelTopical25 mg/1g
PatchTopical
OintmentTopical
OintmentTopical
CreamTopical5550 mg/75g
CreamTopical7.5 g/100g
CreamTopical0.6 g/12g
CreamCutaneous
StickTopical
StickTopical7.5 %
Ointment; stickTopical
KitTopical
Cloth; creamTopical
PowderTopical
CreamTopical70 mg/1mL
CreamTopical15 mL/200mL
CreamTopical6 mL/100mL
CreamTopical5.49 g/100g
CreamTopical3 g/50g
CreamTopical6 %
StickOral
EmulsionTopical75 mg/1mL
LipstickTopical5 g/100g
StickTopical306 mg/9g
EmulsionTopical1690 mg/34.48g
CreamTopical1690 mg/34.48g
CreamTopical2 mg/1mL
LipstickTopical0.07 g/1g
LiquidTopical3 g/100mL
PowderTopical0.05 g/1g
LiquidTopical6 g/100mL
SprayTopical
PasteTopical75 mg/1mL
PowderTopical
PowderTopical5 g/100g
EmulsionTopical74.9 mg/1mL
LotionTopical74.9 mg/1mL
LiquidTopical2.2 mL/100mL
CreamTopical3.75 mg/50mL
CreamTopical7.5 g/100mL
LiquidTopical7.5 g/100g
CreamTopical7 g/100g
LipstickTopical0.072 g/1g
PowderTopical0.06 g/1g
LipstickTopical0.068 g/1g
LipstickTopical0.075 g/1g
CreamTopical0.6 g/15mL
CreamTopical2 g/50mL
CreamTopical2 g/40mL
EmulsionTopical18.75 mL/250mL
LotionTopical1.1988 mL/30mL
LipstickTopical69 mg/1g
StickTopical68 mg/1g
LipstickTopical68 mg/1g
CreamTopical10 mg/1mL
CreamTopical28 mg/1mL
PowderTopical50 mg/1g
AerosolTopical50 mg/1mL
LipstickTopical122.5 mg/3.5g
EmulsionTopical30 mg/1mL
EmulsionTopical3 g/100g
Liquid; lotionTopical
LiquidTopical2.20 mL/100mL
CreamTopical3 mL/75mL
LotionTopical20 mg/1mL
CreamTopical50 mg/1g
EmulsionTopical49.9 mg/1mL
LotionTopical67 mg/1mL
StickCutaneous
CreamTopical3 mL/100mL
LipstickTopical75 mg/1mL
LipstickTopical74 mg/1mL
SprayTopical
LipstickTopical225 mg/3g
LipstickTopical525 mg/7g
SprayTopical9.75 mL/130mL
CreamTopical2.25 mL/30mL
CreamTopical1.5 g/30g
CreamTopical1.5 mL/30mL
LotionTopical2275 mg/35mL
Kit
SoapTopical
OilTopical
CreamTopical3.75 mL/50mL
LotionTopical50 mg/1mL
LiquidTopical75 mg/1mL
PowderTopical0.975 g/13g
LiquidTopical0.72 mL/24mL
LotionTopical0.9 mL/30mL
LiquidTopical0.9 mL/30mL
PowderTopical75 mg/1g
StickTopical0.12 g/4g
LotionTopical1.95 g/30mL
CreamTopical35 mg/1mL
CreamTopical3.5 g/100g
LotionTopical35 mg/1mL
LotionTopical3.5 g/100mL
SuspensionTopical
LotionTopical2.1 g/30mL
LiquidTopical0.07 g/1mL
LiquidTopical0.045 g/1g
CreamTopical1.35 g/30g
Lotion / shampooTopical
JellyTopical
CreamTopical6 mL/30mL
CreamTopical1.8 g/30mL
LiquidTopical30 mg/1mL
LiquidTopical70 mg/1mL
CreamTopical49 mg/1g
LotionTopical75 mg/1mL
LiquidTopical60 mg/1mL
CreamTopical60 mg/1mL
CreamTopical60 mg/100mL
LiquidTopical7 mL/100mL
LiquidTopical7 %
LiquidTopical7.5 %
SolutionTopical
CreamTopical0.525 g/7mL
LotionTopical
CreamTopical
LipstickTopical
LotionTopical0.9 g/30g
LotionTopical30 mg/1mL
LiquidTopical2.1 mL/30mL
LotionTopical70 mg/1mL
LiquidTopical1.5 mL/20mL
LotionTopical45 mg/1mL
PowderTopical40 mg/1g
PowderTopical0.42 g/14g
CreamTopical10 g/100g
LiquidTopical7.5 mL/100mL
LipstickTopical2.2 mL/100mL
LiquidTopical
LiquidTopical
StickTopical222 mg/3g
StickTopical10 mg/1g
StickTopical30 mg/1g
LotionTopical2 g/100mL
CreamTopical7.5 g/30g
EmulsionTopical2.25 g/30g
EmulsionTopical
EmulsionTopical1.5 g/30g
Kit; lotionTopical
CreamTopical1.5 g/100g
LotionTopical0.05 g/1mL
LiquidNot applicable1 L/1L
CreamTopical3.5 g/50mL
OilTopical16.8 mg/1mL
OilTopical19.3 mg/1mL
SprayTopical19.8 mg/1mL
OilTopical2 g/100g
LotionCutaneous
CreamTopical11.25 mL/150mL
CreamTopical3.75 g/50mL
CreamTopical50 mg/1mL
LiquidTopical50 mg/1mL
LipstickTopical3.5 g/100g
Cream; kitTopical
PowderCutaneous
CreamTopical7.5 mL/100mL
CreamTopical1.3 g/30mL
LiquidTopical4 g/100mL
PasteTopical7.5 g/100g
LipstickTopical7.5 g/100g
LipstickTopical0.28 g/4g
LotionTopical2.25 g/30mL
SuspensionTopical7.5 %
GelTopical3 g/100mL
CreamTopical4 g/100mL
SuspensionTopical
LipstickTopical20 mg/1mL
CreamTopical2036 mg/30mL
CreamTopical1832 mg/30mL
StickTopical196 mg/4g
LipstickTopical196 mg/4g
StickTopical4.996 %
LotionTopical1.125 mL/15mL
LotionTopical2.25 mL/30mL
LotionTopical60 mg/1mL
AerosolTopical
LipstickTopical75 mg/1g
CreamTopical
Spray, suspensionTopical
SprayOral
PasteTopical
LiquidTopical2.5 %
GelTopical3.5 mL/100mL
LipstickTopical67.4 mg/1g
PasteTopical67.4 mg/1g
LiquidTopical1.95 g/30mL
SpongeTopical
StickTopical
Liquid; sprayTopical
ClothTopical
SprayTopical16.7 mg/1mL
GelTopical0.075 g/1g
Lotion; sprayTopical
LotionTopical6 g/100mL
EmulsionTopical
CreamTopical30 mg/1mL
CreamTopical75 mg/1mL
LiquidTopical25 mg/1mL
PowderTopical25 mg/1mL
LotionTopical
CreamTopical3 g/100mL
Cream, augmentedTopical
GelTopical
CreamTopical0.36 g/7.2g
CreamTopical68 mg/1mL
CreamTopical2.0 mL/100mL
LipstickTopical7.0 g/100g
CreamTopical6.3 g/100g
LotionTopical5 g/100g
LotionTopical7 g/100g
LipstickTopical210 mg/3g
LipstickTopical0.225 g/3g
Aerosol, foamTopical
Aerosol, sprayTopical
LiquidTopical0.075 mL/1mL
LiquidTopical0.075 g/1mL
Cream; liquidTopical
LiquidTopical5.4 mL/100mL
EmulsionTopical50 mg/1mL
SprayTopical3 g/100g
LiquidTopical40 mg/1mL
LipstickTopical40 mg/1g
LotionTopical3 g/100g
LotionTopical65 mg/1mL
LotionTopical2.1 mL/30mL
LipstickTopical0.076 g/3.8g
PowderTopical0.6 g/10g
CreamTopical74.9 mg/1mL
LotionTopical68 mg/1mL
LotionTopical40 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)-25°CMSDS
boiling point (°C)185-195°C at 1mbarMSDS
water solubility<0.1 g/100 mL at 27°CA19210
logP5.8MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.000452 mg/mLALOGPS
logP5.62ALOGPS
logP5.38ChemAxon
logS-5.8ALOGPS
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity86.44 m3·mol-1ChemAxon
Polarizability34.84 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cinnamic acid esters. These are compound containing an ester derivative of cinnamic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid esters
Direct Parent
Cinnamic acid esters
Alternative Parents
Styrenes / Phenoxy compounds / Methoxybenzenes / Anisoles / Fatty acid esters / Alkyl aryl ethers / Enoate esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Cinnamic acid ester / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Styrene / Alkyl aryl ether / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl
show 13 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on November 30, 2015 12:10 / Updated on November 16, 2019 10:45